(Q36328428)

13 August 2017

1 reference

title

Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach (English)

1 reference

13 August 2017

1 reference

Christian Bogner

1

1 reference

PubMed ID

16321849

13 August 2017

Christian Peschel

series ordinal

2

1 reference

PubMed ID

16321849

13 August 2017

Thomas Decker

series ordinal

3

1 reference

13 August 2017

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

47

1 reference

13 August 2017

2

1 reference

13 August 2017

195-205

1 reference

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

13 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Biology and management of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

The ubiquitin-proteasome proteolytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

How proteolysis drives the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Dual mode of degradation of Cdc25 A phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Arsenite-induced Cdc25C Degradation is through the KEN-box and Ubiquitin-proteasome Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

An essential role for NF-kappaB in preventing TNF-alpha-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Suppression of TNF-alpha-induced apoptosis by NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Bcl-2 activates the transcription factor NFkappaB through the degradation of the cytoplasmic inhibitor IkappaBalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Multiple roles of the tumor suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Proteasome inhibition: a new strategy in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

NF-kappa B: ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Conversion of Bcl-2 to a Bax-like death effector by caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Cellular stress response and apoptosis in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

New drug development in non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500144490

10.1080/10428190500144490

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16321849